Hopp til hovedinnhold

Polymyositt

Sist revidert:
Sist revidert av:
Definisjon:
Inflammatorisk myopati som forekommer i tre hovedformer: polymyositt, dermatomyositt, inklusjonslegememyositt
Forekomst:
Insidensen er 1 per 100.000 per år og er hyppigst blant personer 45-60 år gamle
Symptomer:
Muskelsmerter og ubehag fra andre affiserte organsystemer
Funn:
Muskelømhet ved palpasjon, muskelsvinn, ev. funn fra andre organ
Diagnostikk:
SR og muskelenzymer forhøyet. Ev. positive serologiske prøver. Elektromyografi er unormalt hos nesten alle
Behandling:
Aktuelle medikamenter er kortikosteroider, cyklosporin, azatioprin og metotreksat
  1. Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 2009; 80:1060. PubMed  
  2. Miller ML. Diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults. UpToDate, last updated Apr 22, 2019. UpToDate  
  3. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-82. PubMed  
  4. Seetharaman M. Polymyositis. Medscape, last updated Jun 13, 2020. emedicine.medscape.com  
  5. Koler RA, Montemarano A. Dermatomyositis. Am Fam Physician 2001; 64: 1565-72. PubMed  
  6. Hilton-Jones D. Inflammatory myopathies. Curr Opin Neurol 2001; 14: 591-96. PubMed  
  7. Gran JT. Antisyntetasesyndrom. Tidsskr Nor Lægeforen 2002; 122: 2270-2. PubMed  
  8. Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome. Curr Rheumatol Rep 2011; 13:175. PubMed  
  9. Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin N Am 2002; 28: 779-98. PubMed  
  10. Miller ML. Initial treatment of dermatomyositis and polymyositis in adults. UpToDate, last updated Jul 10, 2019. UpToDate  
  11. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013 Feb. 65(2):314-24. doi:10.1002/art.37754 DOI  
  12. Ueno KI, Shimojima Y, Kishida D, Sekijima Y, Ikeda SI. Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis. Int J Rheum Dis. 2016;19(12):1322-1330. doi:10.1111/1756-185X.12931 DOI  
  13. Carruthers EC, Choi HK, Sayre EC, et al. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. Ann Rheum Dis. 2014 Sep 5. pii: annrheumdis-2014-205800.
  14. Hill CL, Zhang Y, Sigurgeirsson B, et al: Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001 Jan 13; 357(9250): 96-100 PubMed  
  • Terje Johannessen, professor i allmennmedisin, Trondheim (tilpasning til NEL)

Tidligere fagmedarbeidere

  • Gunnar Husby, professor i revmatologi, Oslo Sanitetsforenings Revmatismesykehus, Universitetet i Oslo og Rikshospitalet, Oslo